127 related articles for article (PubMed ID: 11725821)
1. A behavioural pattern analysis of hypoglutamatergic mice--effects of four different antipsychotic agents.
Nilsson M; Waters S; Waters N; Carlsson A; Carlsson ML
J Neural Transm (Vienna); 2001; 108(10):1181-96. PubMed ID: 11725821
[TBL] [Abstract][Full Text] [Related]
2. The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition.
Nilsson M; Carlsson A; Markinhuhta KR; Sonesson C; Pettersson F; Gullme M; Carlsson ML
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jul; 28(4):677-85. PubMed ID: 15276693
[TBL] [Abstract][Full Text] [Related]
3. Co-administration of 5-HT6 receptor antagonists with clozapine, risperidone, and a 5-HT2A receptor antagonist: effects on prepulse inhibition in rats.
Fijał K; Popik P; Nikiforuk A
Psychopharmacology (Berl); 2014 Jan; 231(1):269-81. PubMed ID: 23954911
[TBL] [Abstract][Full Text] [Related]
4. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone.
Martin P; Waters N; Schmidt CJ; Carlsson A; Carlsson ML
J Neural Transm (Vienna); 1998; 105(4-5):365-96. PubMed ID: 9720968
[TBL] [Abstract][Full Text] [Related]
5. The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice.
Carlsson ML; Martin P; Nilsson M; Sorensen SM; Carlsson A; Waters S; Waters N
J Neural Transm (Vienna); 1999; 106(2):123-9. PubMed ID: 10226932
[TBL] [Abstract][Full Text] [Related]
6. M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats.
Varty GB; Bakshi VP; Geyer MA
Neuropsychopharmacology; 1999 Apr; 20(4):311-21. PubMed ID: 10088132
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of classical neuroleptics and a newer generation antipsychotics on the MK-801 induced behavioural primitivization in mouse.
Nilsson M; Markinhuhta KR; Carlsson ML
Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):521-30. PubMed ID: 16414166
[TBL] [Abstract][Full Text] [Related]
8. M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice.
Wang RY; Liang X
Neuropsychopharmacology; 1998 Jul; 19(1):74-85. PubMed ID: 9608579
[TBL] [Abstract][Full Text] [Related]
9. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
[TBL] [Abstract][Full Text] [Related]
10. MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride.
Martin P; Waters N; Waters S; Carlsson A; Carlsson ML
Eur J Pharmacol; 1997 Sep; 335(2-3):107-16. PubMed ID: 9369362
[TBL] [Abstract][Full Text] [Related]
11. The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating.
Bubeníková V; Votava M; Horácek J; Pálenícek T; Dockery C
Pharmacol Biochem Behav; 2005 Apr; 80(4):591-6. PubMed ID: 15820528
[TBL] [Abstract][Full Text] [Related]
12. The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats.
Rung JP; Carlsson A; Markinhuhta KR; Carlsson ML
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jun; 29(5):833-9. PubMed ID: 15913873
[TBL] [Abstract][Full Text] [Related]
13. Effects of 5-hydroxytryptamine2 receptor antagonism on the behavioral activation and immediate early gene expression induced by dizocilpine.
O'Neill MF; Hicks CA; Shaw G; Parameswaran T; Cardwell GP; O'Neill MJ
J Pharmacol Exp Ther; 1998 Dec; 287(3):839-46. PubMed ID: 9864262
[TBL] [Abstract][Full Text] [Related]
14. Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action.
López-Gil X; Artigas F; Adell A
Int J Neuropsychopharmacol; 2009 May; 12(4):487-99. PubMed ID: 18752722
[TBL] [Abstract][Full Text] [Related]
15. M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro.
Arvanov VL; Wang RY
Neuropsychopharmacology; 1998 Mar; 18(3):197-209. PubMed ID: 9471117
[TBL] [Abstract][Full Text] [Related]
16. The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. (Rapid communication).
Martin P; Waters N; Carlsson A; Carlsson ML
J Neural Transm (Vienna); 1997; 104(4-5):561-4. PubMed ID: 9295186
[TBL] [Abstract][Full Text] [Related]
17. Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward.
Benaliouad F; Kapur S; Rompré PP
Neuropsychopharmacology; 2007 Mar; 32(3):551-61. PubMed ID: 16794561
[TBL] [Abstract][Full Text] [Related]
18. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat.
López-Gil X; Babot Z; Amargós-Bosch M; Suñol C; Artigas F; Adell A
Neuropsychopharmacology; 2007 Oct; 32(10):2087-97. PubMed ID: 17356574
[TBL] [Abstract][Full Text] [Related]
19. Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors.
Maurel-Remy S; Bervoets K; Millan MJ
Eur J Pharmacol; 1995 Jul; 280(2):R9-11. PubMed ID: 7589172
[TBL] [Abstract][Full Text] [Related]
20. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.
Kehne JH; Baron BM; Carr AA; Chaney SF; Elands J; Feldman DJ; Frank RA; van Giersbergen PL; McCloskey TC; Johnson MP; McCarty DR; Poirot M; Senyah Y; Siegel BW; Widmaier C
J Pharmacol Exp Ther; 1996 May; 277(2):968-81. PubMed ID: 8627580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
